A Phase 4 interventional study of Leuprolide in Prostate Cancer, sponsored by Astellas Pharma Singapore Pte. Ltd.. Completed at 19 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Astellas Pharma Singapore Pte. Ltd. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 28th largest by enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2017, is one of 9 in phase 4, and was the 44th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Ontario Clinical Oncology Group (OCOG) · Sites in Canada
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 27 · Phase 4 9
First in 1994; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 107 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 77 across the 69 interventional studies. Of the 47 that completed or were terminated, 26 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 70 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Singapore Pte. Ltd., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Singapore Pte. Ltd. is the lead sponsor of 9 studies on the registry; none are open to participants now.
53 studies in Prostatic Neoplasms by Astellas Pharma Inc: 5 open now, 7 under way, 1 of them phase 3. Of 46 finished, 13 (28%) have results posted.
Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, this one is the 18th largest by enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2017, is one of 7 in phase 4, and was the 41st registered.
Astellas Pharma Inc’s Prostatic Neoplasms studies by the year they started, since 2001.
7 of the studies testing leuprolide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT04302454Phase 3University Medical Center GroningenAndrogen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy | 2027-10-21 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT04249154McGill University Health Centre/Research Institute of the McGill University Health CentrePostop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer | 2026-12-15 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, from their registry updates:
Among Astellas Pharma Inc’s 53 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to evaluate the safety profile of ELIGARD® in ethnic Asian prostate cancer patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 22.5 mg of leuprolide acetate (eligard) by subcutaneous injection at baseline, month 3, 6, 9, 12 and 15.
Drug: Leuprolide
Subcutaneous Injection
Also known as: Eligard
Number of Participants With Eligard Related Adverse Events (AE)
An AE was defined as any untoward medical occurrence in a participant administered a study drug or had undergone study procedures that did not necessarily have a causal relationship with this treatment. An AE was considered to be serious if, in the view of either the investigator or sponsor, it resulted in any of the following outcomes: resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization, other medically important events. Drug-related AEs are AEs where causal relationships were at least a reasonable possibility as determined by the investigator.
Time frame: From first dose of study drug up to 18 months
Percentage of Participants With Testosterone Levels Less Than (<) 20, 20-50 and Greater Than (>) 50 Nanogram Per Deciliter (ng/dL) at Month 12
Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.
Time frame: Month 12
Percentage of Participants With Testosterone Levels < 20, 20-50 and > 50 ng/dL at Month 18
Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.
Time frame: Month 18
Time to PSA Progression
Time to PSA progression was defined as (date of ≥25 percentage (%) increase and ≥ 2 ng/mL absolute increase) - (date of first administration of ELIGARD 22.5 mg)/30, where PSA progression was defiined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis.
Time frame: From first dose of study drug up to PSA progression (18 months)
Percentage of Participants With Greater Than or Equal to (≥) 30% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18
PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 30% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL), and confirmed by a second value at least 3 weeks later.
Time frame: Months 3, 6, 9, 12, 15 and 18
Percentage of Participants With ≥50% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18
PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 50% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.
Time frame: Months 3, 6, 9, 12, 15 and 18
Percentage of Participants With ≥90% PSA Percent Reduction From Baseline at Month 3, 6, 9, 12, 15, and 18
PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 90%, with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.
Time frame: Months 3, 6, 9, 12, 15 and 18
Change From Baseline in EQ-5D-5L Health State Utility Index Score (Japan) at Months 6, 12 and 18
EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using Japan value sets. Scores ranged from -0.111 to 1. Higher scores indicate better health state.
Time frame: Baseline, months 6, 12 and 18
Change From Baseline in EQ-5D-5L Health Status Utility Index Score (UK) at Months 6, 12 and 18
EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using UK value sets. Scores ranged from -0.594 to 1. Higher scores indicate better health state.
Time frame: Baseline, months 6, 12 and 18
Change From Baseline in EQ-5D-5L Health Status Utility Index Score (US) at Months 6, 12 and 18
EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participants was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using US value sets. Scores ranged from -0.109 to 1. Higher scores indicate better health state.
Time frame: Baseline, months 6, 12 and 18
Change From Baseline in EQ-5D02-EQ-VAS Score at Months 6, 12 and 18
The EQ5D02-EQ-VAS is a vertical VAS with values between 0 (worst imaginable health) and 100 (best imaginable health), on which participants provide a global assessment of their health. Higher score indicate better health state.
Time frame: Baseline, months 6, 12 and 18
Change From Baseline in EORTC QLQ-PR25 Score at Months 6, 12 and 18
EORTC QLQ-PR25 is a prostate cancer module for the assessment of health-related quality of life (HRQoL). EORTC QLQ-PR25 is designed for self-completion by respondents and assesses urinary symptoms, bowel symptoms, treatment-related symptoms and sexual activity and functioning. The rule of scoring for EORTC QLQ-PR25 follows instruction of EORTC QLQ-PR25 Scoring Manual 2.0. It consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).
Time frame: Baseline, months 6, 12 and 18
Asian male participants above the age of 18 years with biopsy-proven prostate adenocarcinoma who fulfill the eligibility criteria were enrolled in this study.
| Milestone | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Started | 107 |
| Completed | 64 |
| Not completed | 43 |
| Withdrew: Adverse event | 2 |
| Withdrew: Death | 9 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Progressive disease | 22 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Physician decision | 5 |
An AE was defined as any untoward medical occurrence in a participant administered a study drug or had undergone study procedures that did not necessarily have a causal relationship with this treatment. An AE was considered to be serious if, in the view of either the investigator or sponsor, it resulted in any of the following outcomes: resulted in death, was life-threatening, resulted in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, resulted in congenital anomaly or birth defect, required inpatient hospitalization or led to prolongation of hospitalization, other medically important events. Drug-related AEs are AEs where causal relationships were at least a reasonable possibility as determined by the investigator.
| Participants | Leuprolide Acetate 22.5 mg |
|---|---|
| Drug-related adverse event | 15 |
| Drug-related serious adverse event | 2 |
Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.
| Percentage of participants | Leuprolide Acetate 22.5 mg |
|---|---|
| < 20 ng/dL | 51.4 |
| 20 - 50 ng/dL | 12.4 |
| > 50 ng/dL | 1.9 |
Testosterone level was summarized based on the percentage of participants with \< 20 ng/dL, 20 to 50 ng/dL and \> 50 ng/dL.
| Percentage of participants | Leuprolide Acetate 22.5 mg |
|---|---|
| < 20 ng/dL | 61.9 |
| 20 - 50 ng/dL | 16.2 |
| > 50 ng/dL | 1.9 |
Time to PSA progression was defined as (date of ≥25 percentage (%) increase and ≥ 2 ng/mL absolute increase) - (date of first administration of ELIGARD 22.5 mg)/30, where PSA progression was defiined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis.
| Months | Leuprolide Acetate 22.5 mg |
|---|---|
| Time to PSA Progression | 8.80 (6.10 to 9.20) |
PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 30% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 nanogram per milliliter (ng/mL), and confirmed by a second value at least 3 weeks later.
| Percentage of participants | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 3 | 96.1 |
| Month 6 | 93.8 |
| Month 9 | 92.8 |
| Month 12 | 97.1 |
| Month 15 | 98.4 |
| Month 18 | 91.0 |
PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 50% with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.
| Percentage of participants | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 3 | 89.2 |
| Month 6 | 91.7 |
| Month 9 | 91.6 |
| Month 12 | 94.2 |
| Month 15 | 96.9 |
| Month 18 | 88.8 |
PSA percent reduction (%) = (\[PSA tested- baseline PSA\]/baseline PSA)\*100%. PSA level was summarized based on time to PSA progression and PSA percent reduction by ≥ 90%, with respect to the level at baseline. Participants with more than 1 qualifying PSA progression were counted only once, and the earlier progression was accounted for time to progression analysis. PSA progression was defined as 25% or greater increase and an absolute increase of 2 ng/mL, and confirmed by a second value at least 3 weeks later.
| Percentage of participants | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 3 | 69.6 |
| Month 6 | 77.1 |
| Month 9 | 77.1 |
| Month 12 | 81.2 |
| Month 15 | 79.7 |
| Month 18 | 68.5 |
EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using Japan value sets. Scores ranged from -0.111 to 1. Higher scores indicate better health state.
| Score on a scale | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 6 | -0.0047 ± 0.16874 |
| Month 12 | -0.0093 ± 0.14456 |
| Month 18 | -0.0262 ± 0.17520 |
EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participant was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using UK value sets. Scores ranged from -0.594 to 1. Higher scores indicate better health state.
| Score on a scale | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 6 | 0.0055 ± 0.21662 |
| Month 9 | -0.0051 ± 0.16493 |
| Month 18 | -0.0259 ± 0.23831 |
EQ-5D-5L is a standardized instrument for use as a measure of health outcome and provides a simple descriptive profile and a single index value for health status. EQ-5D-5L is designed for self-completion by respondents and consists of 2 pages comprising the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension of the EQ-5D-5L has 5 levels (no problems, slight problems, moderate problems, severe problems, and extreme problems) and the participants was asked to indicate his health state by ticking the box with the most appropriate statement. Index scores were generated using US value sets. Scores ranged from -0.109 to 1. Higher scores indicate better health state.
| Score on a scale | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 6 | 0.0017 ± 0.15819 |
| Month 9 | -0.0047 ± 0.12477 |
| Month 18 | -0.0191 ± 0.16934 |
The EQ5D02-EQ-VAS is a vertical VAS with values between 0 (worst imaginable health) and 100 (best imaginable health), on which participants provide a global assessment of their health. Higher score indicate better health state.
| Score on a scale | Leuprolide Acetate 22.5 mg |
|---|---|
| Month 6 | 1.3 ± 14.72 |
| Month 9 | 2.1 ± 11.92 |
| Month 18 | 2.0 ± 15.65 |
EORTC QLQ-PR25 is a prostate cancer module for the assessment of health-related quality of life (HRQoL). EORTC QLQ-PR25 is designed for self-completion by respondents and assesses urinary symptoms, bowel symptoms, treatment-related symptoms and sexual activity and functioning. The rule of scoring for EORTC QLQ-PR25 follows instruction of EORTC QLQ-PR25 Scoring Manual 2.0. It consist of 25 questions distributed on 6 domains: urinary symptoms (8 items), incontinence aid (1 item), bowel symptoms (4 items), hormonal treatment-related symptoms (HTRS) (6 items), sexual activity (2 items), and sexual functioning (4 items). Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale, with higher scores reflecting either more symptoms (urinary, bowel, hormonal treatment-related symptoms) or higher levels of activity or functioning (sexual).
| Score on a scale | Leuprolide Acetate 22.5 mg |
|---|---|
| Week 6: Urinary Symptoms | -4.84 ± 15.669 |
| Week 6: Incontinence Aid | -5.21 ± 28.220 |
| Week 6: Bowel Symptoms | -2.17 ± 8.311 |
| Week 6: HTRS | 3.27 ± 11.008 |
| Week 6: Sexually Active | -6.08 ± 17.290 |
| Week 6: Sexual Function | -1.44 ± 11.362 |
| Week 12: Urinary Symptoms | -6.93 ± 15.237 |
| Week 12: Incontinence Aid | -11.11 ± 32.338 |
| Week 12: Bowel Symptoms | -2.66 ± 9.533 |
| Week 12: HTRS | 2.14 ± 9.959 |
| Week 12: Sexually Active | -5.07 ± 16.983 |
| Week 12: Sexual Function | -2.99 ± 14.823 |
| Week 18: Urinary Symptoms | -4.06 ± 15.370 |
| Week 18: Incontinence Aid | 1.67 ± 31.484 |
| Week 18: Bowel Symptoms | 0.31 ± 9.036 |
| Week 18: HTRS | 4.68 ± 11.064 |
| Week 18: Sexually Active | -3.54 ± 23.334 |
| Week 18: Sexual Function | -8.52 ± 15.969 |
Collected over From first dose of study drug up to 18 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate 22.5 mg | 9/106 (8.5%) | 31/106 (29.2%) | 42/106 (39.6%) |
| Event | Leuprolide Acetate 22.5 mg |
|---|---|
| PneumoniaInfections and infestations | 4/106 |
| DeathGeneral disorders | 3/106 |
| AnaemiaBlood and lymphatic system disorders | 2/106 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/106 |
| Back painMusculoskeletal and connective tissue disorders | 2/106 |
| Haemorrhage intracranialNervous system disorders | 2/106 |
| NeuralgiaNervous system disorders | 2/106 |
| Cardiac failure congestiveCardiac disorders | 1/106 |
| Abdominal wall haematomaGastrointestinal disorders | 1/106 |
| Anal hypoaesthesiaGastrointestinal disorders | 1/106 |
| Event | Leuprolide Acetate 22.5 mg |
|---|---|
| Prostatic specific antigen increasedInvestigations | 18/106 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/106 |
| Back painMusculoskeletal and connective tissue disorders | 8/106 |
| Hot flushVascular disorders | 8/106 |
| AnaemiaBlood and lymphatic system disorders | 6/106 |
| Upper respiratory tract infectionInfections and infestations | 6/106 |
Safety Analysis Set (SAF) :The SAF consisted of all participants who received at least 1 eligard injection and any follow-up safety information was available.
| Age, Continuous(Years) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Mean | 72.2 ± 7.43 |
| Sex: Female, Male(Participants) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Female | 0 |
| Male | 106 |
| Ethnicity (NIH/OMB)(Participants) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 0 |
| Unknown or Not Reported | 106 |
| Race (NIH/OMB)(Participants) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 106 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Prostate-specific antigen (PSA) Level at Initial Diagnosis(Nanogram per milliliter (ng/mL)) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Mean | 315.05 ± 989.552 |
| EuroQol-5 Dimension-5 Level (EQ-5D-5L) Health State Utility Index Score (Japan)(Score on a scale) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Mean | 0.8162 ± 0.18916 |
| EQ-5D-5L Index Score (UK)(Score on a scale) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Mean | 0.8040 ± 0.25853 |
| EQ-5D-5L Index Score (US)(Score on a scale) | Leuprolide Acetate 22.5 Milligrams (mg) |
|---|---|
| Mean | 0.8503 ± 0.18360 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Jun 2017 to primary completion in Nov 2019, 28 months.
Results were first posted in Dec 2020, 1 year after primary completion.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide
Astellas Pharma Singapore Pte. Ltd. →